Emerging Agents and Biomarkers in Gastric and GEJ Cancers
Daniel Catenacci, MD, and Sam Klempner, MD, conclude their discussion by examining emerging agents and biomarkers for the management of advanced gastric and esophagogastric junction cancers.
Read More
Sequencing After Progression on IO-Based Therapy for mGC
Experts in the management of gastric cancer discuss best practices for monitoring signs and symptoms of disease progression and explore factors to consider when switching therapies in later lines of treatment.
Read More
Frontline Therapy for Metastatic PD-L1–, HER2+ Gastric Cancer
Gastric cancer specialists emphasize the importance of communication and education when selecting first-line treatment for patients with PD-L1-negative, HER2-positive disease.
Read More
Biomarker Testing for Gastric and GEJ Cancers
Experts in gastrointestinal oncology review the challenges associated with molecular testing and the role of biomarker testing on disease management.
Read More
KEYNOTE-811: IO-Based Therapy for HER2+ Gastric Cancer
Sam Klempner, MD, and Daniel Catenacci, MD, discuss the KEYNOTE-811 study of pembrolizumab plus trastuzumab in combination with chemotherapy in patients with HER2-positive disease.
Read More
CHECKMATE649: Safety Profile and Toxicity Management
Thought leaders in gastric and GEJ cancers review safety outcomes from the CHECKMATE649 trial presented at the 2021 ASCO annual meeting.
Read More
CHECKMATE649: Trial Design and Efficacy Data
Key opinion leader in gastric cancer, Daniel Catenacci, MD, leads a discussion on the study design, patient population, and results from the CHECKMATE649 trial of nivolumab and chemotherapy in patients with gastric or GEJ cancers.
Read More
Recent FDA Approvals in Gastric and GEJ Cancers
Daniel Catenacci, MD, and Sam Klempner, MD, consider the overall impact of recently approved immunotherapy-based regimens for gastric and gastroesophageal junction cancers.
Read More
Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer
March 1st 2018Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.
Read More
Dr. Catenacci on Results of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer
January 20th 2018Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.
Read More